PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Hamad Medical Corporation, Doha, Qatar.\', \'Biomedical Research Center, Qatar University, Doha, Qatar.\', \'Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.\', \'Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.\', \'World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.\', \'College of Health Sciences, QU Health, Qatar University, Doha, Qatar.\', \'Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.\', \'Primary Health Care Corporation, Doha, Qatar.\', \'Ministry of Public Health, Doha, Qatar.\', \'Department of Pathology, Sidra Medicine, Doha, Qatar.\', \'Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1371/journal.pone.0262897
?:doi
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 35100295
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
?:title
  • Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all